Cash and short-term investments balance as of December 31, 2023 expected to be $66.5 million, which includes net proceeds of approximately $7.9 million raised in the fourth quarter from an at-the-market equity financing facility, as well as a portion of the proceeds from its biotechnology company data collaboration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NPCE:
- NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
- NeuroPace ‘primed for continued outperformance’ in 2024, says Lake Street
- NeuroPace announces early completion of patient enrollment in NAUTILUS study
- NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
- NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
